New Insights into the Role of Metformin Effects on Serum Omentin-1 Levels in Acute Myocardial Infarction: Cross-Sectional Study
Table 3
Biochemical changes and serum omentin-1 levels in acute MI in the patients that were not previously treated with metformin prior to acute MI in comparison with normal healthy control subjects.
Biochemical parameters
Group III () Mean ± SD
Group II () Mean ± SD
95% CI Upper-lower limits
p
S. omentin-1 pg/mL
27.13 ± 1.55
23.71 ± 1.161
12.0852
27.7088–26.5512
<0.0001
S. troponin-I pg/mL
21.202 ± 2.636
79.53 ± 3.60
−121.197
22.1863–20.2177
<0.0001
FBG mg/dL
118.96 ± 9.704
138.77 ± 17.467
−11.181
122.5835–115.3365
<0.0001
Total cholesterol mg/dL
140.96 ± 30.091
242.44 ± 12.552
−18.4716
152.1962–129.7238
<0.0001
TG mg/dL
138.66 ± 10.366
246.55 ± 57.607
−57.007
142.530–134.7893
<0.0001
HDL-C mg/dL
51.23 ± 5.882
38.77 ± 4.570
11.6026
53.4264–49.0336
<0.0001
VLDL-C mg/dL
27.64 ± 2.082
49.30 ± 11.524
−56.9821
28.4174–26.8626
<0.0001
LDL-C mg/dL
62.08 ± 3.834
154.37 ± 4.316
−722.133
62.3414–61.8186
<0.0001
AI
0.072 ± 0.008
0.443 ± 0.0084
−254.006
0.075–0.069
<0.0001
SPB mmHg
123.16 ± 9.042
162.33 ± 10.61
−23.727
126.5363–119.7837
<0.0001
DPB mmHg
75.50 ± 11.643
105.16 ± 21.784
−13.953
79.8476–71.1524
<0.0001
Group II: patients have not received metformin prior to acute MI. Group III: normal healthy controls have not received any drugs. . FBG: fasting blood glucose, TG: triglyceride, HDL: high density lipoprotein, VLDL: very low density lipoprotein, LDL: low density lipoprotein, AI: atherogenic index, SPB: systolic blood pressure, and DPB: diastolic blood pressure.
